Armata Pharmaceuticals (ARMP) Cash & Equivalents (2013 - 2026)

Armata Pharmaceuticals has disclosed Cash & Equivalents across 14 years of filings, most recently posting $4.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $4.8 million, down 59.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (down 59.33% YoY), and the FY2025 annual result was $8.7 million, down 6.49% from the prior year.
• Cash & Equivalents came in at $4.8 million for Q1 2026 at Armata Pharmaceuticals, down from $8.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $46.4 million in Q1 2022 to a low of $4.3 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $14.9 million (2022), against an average of $19.6 million.
• Across the five-year window, Cash & Equivalents surged 111.99% in 2024 and slumped 83.72% in 2025, its largest moves.
• Armata Pharmaceuticals' Cash & Equivalents stood at $14.9 million in 2022, then decreased by 8.95% to $13.5 million in 2023, then plunged by 31.29% to $9.3 million in 2024, then fell by 6.49% to $8.7 million in 2025, then tumbled by 45.28% to $4.8 million in 2026.
• The last three Cash & Equivalents figures came in at $4.8 million (Q1 2026), $8.7 million (Q4 2025), and $14.8 million (Q3 2025), per Business Quant data.